PMID- 26168132
OWN - NLM
STAT- MEDLINE
DCOM- 20160425
LR  - 20210217
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 22
IP  - 3
DP  - 2014
TI  - HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib 
      in Breast Cancer Model.
PG  - 139-45
LID - 10.3727/096504014X13983417587366 [doi]
AB  - Antiangiogenic therapy is a promising strategy for cancer therapy. However, 
      antiangiogenic therapy can induce intratumor hypoxia and hypoxia-inducible 
      factor-1 (HIF-1) expression, which slows cancer progression. In our present 
      study, we found that antiangiogenic therapy with sunitinib plus HIF-1 
      dimerization inhibitor acriflavine retarded tumor growth in a murine model of 
      breast cancer. The combination of sunitinib with acriflavine significantly 
      decreased vascular endothelial growth factor and TGF-beta expression and reduced 
      tumor vasculature followed by increased intratumor necrosis and apoptosis. 
      Moreover, decreased accumulation of myeloid-derived suppressor cells in the 
      spleen was observed after the combinational therapy. In conclusion, the 
      combination of HIF-1 inhibition and antiangiogenic therapy may represent a novel 
      strategy for cancer patients.
FAU - Yin, Tao
AU  - Yin T
AD  - State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, 
      West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 
      PR China.
FAU - He, Sisi
AU  - He S
FAU - Shen, Guobo
AU  - Shen G
FAU - Wang, Yongsheng
AU  - Wang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (vascular endothelial growth factor A, mouse)
RN  - 1T3A50395T (Acriflavine)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Acriflavine/*therapeutic use
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Disease Models, Animal
MH  - Drug Synergism
MH  - Female
MH  - Hypoxia-Inducible Factor 1/*metabolism
MH  - Indoles/*therapeutic use
MH  - Mammary Neoplasms, Experimental/blood supply/*drug therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Myeloid Cells/cytology
MH  - Necrosis/pathology
MH  - Neovascularization, Pathologic/*drug therapy
MH  - Protein Multimerization/drug effects
MH  - Pyrroles/*therapeutic use
MH  - Spleen/cytology
MH  - Sunitinib
MH  - Transforming Growth Factor beta/metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
PMC - PMC7838425
COIS- The authors declare no conflicts of interest.
EDAT- 2015/07/15 06:00
MHDA- 2016/04/26 06:00
PMCR- 2015/07/16
CRDT- 2015/07/14 06:00
PHST- 2015/07/14 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2016/04/26 06:00 [medline]
PHST- 2015/07/16 00:00 [pmc-release]
AID - OR786 [pii]
AID - 10.3727/096504014X13983417587366 [doi]
PST - ppublish
SO  - Oncol Res. 2014;22(3):139-45. doi: 10.3727/096504014X13983417587366.